KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Debt (2016 - 2025)

Historic Total Debt for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q3 2025 value amounting to $121.3 million.

  • Alnylam Pharmaceuticals' Total Debt changed N/A to $121.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year change of. This contributed to the annual value of $93.8 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Total Debt stood at $121.3 million.
  • In the past 5 years, Alnylam Pharmaceuticals' Total Debt ranged from a high of $675.7 million in Q4 2021 and a low of $93.8 million during Q4 2024
  • For the 3-year period, Alnylam Pharmaceuticals' Total Debt averaged around $225.9 million, with its median value being $120.8 million (2025).
  • The largest annual percentage gain for Alnylam Pharmaceuticals' Total Debt in the last 5 years was 25325.39% (2021), contrasted with its biggest fall of 25325.39% (2021).
  • Quarter analysis of 3 years shows Alnylam Pharmaceuticals' Total Debt stood at $675.7 million in 2021, then plummeted by 86.12% to $93.8 million in 2024, then rose by 29.32% to $121.3 million in 2025.
  • Its Total Debt stands at $121.3 million for Q3 2025, versus $120.8 million for Q2 2025 and $118.1 million for Q1 2025.